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correlations between the slope, D5 v, D2 v, HRCTV D90, 
HRCTV volume, and the RV point. 
 
Results: Total doses from 3 fractions for the D5 v median 
48.7Gy (range 31.4 - 76.6Gy), D2 v median 64.0Gy (range: 
43.2 - 112Gy) and RV median dose 16.3Gy (range: 11.6 – 
25.3Gy) The RV point exhibited a weak correlation with D2 v 
(r=0.56; p=0.0001) and D5 v (r = 0.55; p=0.0001) respectively. 
A moderate correlation was observed between the HRCTV 
volume and the D2 v (r = 0.69; p=0.0001), the HRCTV volume 
and D5 v (r = 0.73; p=0.0001) and a weak correlation with the 
HRCTV volume and the RV Point (r=0.57; p=0.0001). The 
slope correlated with D2 v (r= -0.96; p=0.0001) and D5 v (r=-
0.87; p=0.0001) and a weak correlation with the RV point (r=-
0.52; p=0.0002). No correlation was found between the 
HRCTV D90 and the D2v (r=-0.20; p=0.1826), the D5v (r=-
0.24; p=0.1082), or the RV Point (r=0.02; p=0.8431). 
 
Conclusion: The expansion volume of the ring applicator cap 
can provide a suitable surrogate for determining the vaginal 
mucosa dose, as this part of the vagina is in close proximity 
to the ring and tandem contributing to the volume of vaginal 
mucosa receiving the highest vaginal dose. The RV point does 
not correlate with the D2v and D5v and therefore can not to 
be use as a suitable surrogate point for the dose to the 
vaginal mucosa. Additional work is currently ongoing to 
correlate the D2v and D5v with clinically measured vaginal 
morbidity. 
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Purpose or Objective: In order to evaluate the usefulness of 
high-dose-rate image-guided interstitial brachytherapy (HDR-
ISBT) for recurrent uterine cervical adenocarcinoma, we 
analyzed our clinical experience. 
 
Material and Methods: We investigated 28 patients treated 
with HDR-ISBT at National Hospital Organization Osaka 
National Hospital between May 2003 and December 2010. All 
patients received radical surgery and 7 patients also received 
post-operative radiotherapy as previous treatments. 
Histologic finding was adenocarcinoma and squamous cell 
carcinoma for 11 and 17 patients. In 11 adenocarcinoma 
patients, 6 patients had endometrioid adenocarcinoma and 
the other 5 patients had mucinous adenocarcinoma. The 
median tumor size was 23 mm (range; 5-79 mm). In 21 
patients who had no irradiation history, 9 patients were 
treated with HDR-ISBT alone and the other 12 patients were 
treated with HDR-ISBT plus external beam radiotherapy 
(EBRT). Forty-eight to 54 Gy in 8 to 9 fractions were 
delivered as monotherapy and 30 to 33 Gy in 5 to 6 fractions 
as combination of EBRT. In 7 patients who had irradiation 
history, slight lower doses (42 to 48 Gy in 7 to 8 fractions) 
were selected. We implanted 7–15 (median, 12) applicators 
under transrectal ultrasonography guidance. We used free-
hand implantation with ambulatory technique for later 25 
patients. Magnetic resonance imaging (MRI)-assisted image-
based treatment planning was performed for later 17 
patients. Clinical target volumes (CTV) were the gloss tumor 
volume with or without 10 mm of vaginal margin for patients 
with or without non-irradiation history. 
 
Results: The median follow-up time was 43 months (range; 4-
115 months). The median D90(CTV)s were 120%prescribed 
dose (PD), 122%PD and 118%PD for patients who had 
endometrioid adenocarcinoma, mucinous adenocarcinoma 
and squamous cell carcinoma. The 3-year local control and 
overall survival rates were 72% and 73% for adenocarcinoma. 
The 3-year local control and overall survival rates were 88% 
and 77% for squamous cell carcinoma. No significant 
difference was observed. The 3-year local control rates were 
both 67% for endometrioid adenocarcinoma and mucinous 
adenocarcinoma. Grade 3-4 late complications occurred by 
HDR-ISBT in 5 patients (18%). 
 
Conclusion: Our treatment result of image-based HDR-ISBT 
showed that slight inferior result was observed in cervical 
adenocarcinoma although there was no significant difference. 
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Purpose or Objective: Brachytherapy is one the most 
important components in the treatment of cervical cancer. 
Recently 3D planning for brachytherapy has been used which 
could be done both by CT and MRI imaging based. We 
compared the high risk clinical target volumes contoured on 
CT and MRI and dose distribution in the target volumes and 
organs at risk. 
 
Material and Methods: Twenty three patients with IIA-IIIB 
stage cervical cancer were planned for HDR brachytherapy 
with ring-tandem applicators. Treatment consisted of four 7 
Gy fractions by two insertion procedures. On MRI and CT sets 
we contoured HR CTV and organs at risk on 42 plans: for 19 
patients two plans and for four patients only one. Medical 
physicists received task to make planning on CT and MRI 
images independently at the same day before irradiation. 
The mean HR CTV volume, dose received by at least 90% of 
the volume (D90) and the dose to 2 cc for the organs at risk 
were evaluated. 
 
Results: The mean volume of HR CTV was 77.5 cc on CT 
based contours and 60.3 cc on MRI imaging. This difference in 
HR CTV volume reflected on the dose to organs at risk – 
physicists have to increase it to achieve prescribed dose in 
target volume. Thus, while assessing mean D2cc for rectum, 
bladder and sigmoid we find out that it was lower in case of 
MRI based planning compare to CT based planning – 66.2 Gy 
and 70.3 Gy, 85.1 Gy and 89.6 Gy, 62.3 Gy and 66.7 Gy 
respectively. Mean D90 also was significantly higher in MRI 
compared to CT imaging plans – 94,2% versus 79,4% of 
prescribed dose. 
 
Conclusion: In spite that superiority of MRI compared to CT 
imaging based contouring and planning for HR CTV dose 
distribution has been already showed in previous studies we 
found that it also allows indirectly significantly decrease the 
dose to organs at risk during HDR brachytherapy for cervical 
cancer. 
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Purpose or Objective: To retrospectively assess treatment 
outcome of image guided brachytherapy (IGBT) with or 
without hybrid technique for cervical cancer using 
VariSourceTM titanium ring applicator with ‘Siriraj Ring Cap’ 
extension (as figure 1). In case of narrow vaginal opening, 
hybrid brachytherapy technique could be performed using 
this applicator with extension. 
Figure 1: VariSourceTM titanium ring applicator with ‘Siriraj 
Ring Cap’ extension 
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Material and Methods: Between January and December 2014, 
29 patients with locally advanced cervical cancer were 
underwent combination external beam radiotherapy with or 
without concomitant chemotherapy and IGBT with or without 
hybrid technique using VariSourceTM ring applicator with 
‘Siriraj Ring Cap’ extension (at least one fraction). 117 
dosimetric planning and clinical outcome of treatment were 
evaluated. 
 
Results: For high risk clinical target volume (HR CTV) the 
median was volume 37.4 cm3 (range; 15.3-76.1 cm3) and the 
median of D90 was 85.3Gy (range; 76.4-90.5Gy). The median 
of D2cc for bladder, rectum, sigmoid, and bowel loop were 
84Gy (range; 68.3-89.7Gy), 66.1Gy (range; 56.8-76.3Gy), 65.6 
(range; 49-77.1Gy), and 61.9Gy (range; 45.8-78.1Gy), 
respectively. 81.2% (95 of 117 plans) were performed using 
VariSourceTM ring applicator with ‘Siriraj Ring Cap’ 
extension, while mean of coverage of the HR CTV was 89.2% 
(range; 57-99%). 18.8% (22 of 117 plans) were applied using 
tandem with ovoids, and mean of coverage of the HR CTV 
was 79.9% (range; 53-96%). Median follow up was 10.6 
months. The actuarial 1 year loco-regional recurrence free 
survival rate was 90.5% (95% confidence interval (CI); 67-
98%), progression free survival rate was 85.7% (95% CI; 62-
95%), and overall survival rate was 95.4% (95% CI; 71-99%). 
One patient had a grade 2 late rectal complication. No grade 
3-5 late complications have been recorded so far. 
 
Conclusion: IGBT with or without hybrid technique using 
VariSourceTM titanium ring applicator with ‘Siriraj Ring Cap’ 
extension is applicable for locally advanced cervical cancer 
resulting in an excellent local control rate and limited 
morbidity. 
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Purpose or Objective: The effectiveness of radiation therapy 
in the management of cervical cancer of all stages is well 
established. Radiation therapy usually consists of a 
combination of external beam therapy and brachytherapy. 
Further exploration of new approaches and methodologies is 
a promising direction of development. Given the 
radiobiological aspects and an important economic factor, 
i.e. reduction of hospital stay. The aim of this study was to 
estimate the effectiveness of the treatment of cervical 
cancer patients using adaptive image-guided brachytherapy 
(IGBT) during split course. 
 
Material and Methods: In the period from May 2014, 38 
patients with primary cervical cancer were treated with 
combined radiotherapy using the new split-adaptive 
methodology for IGBT. We used conformal radiation 
techniques: BOX method, IMRT or RapidArc. Total dose on the 
pelvic area and regional metastases was 50 Gy. Further HDR 
IGBT brachytherapy was followed with dosimetry planning 
MRI - images. The treatment was on 1st and 2nd , 8th and 9th 
days, ring tandem applicators implantation under general 
anesthesia. Between the fractions 1 and 2 and 3 and 4, the 
patients were with applicator under the supervision of 
medical staff during the day. Monitoring planning was 
conducted according to MRI-studies; as a result treatment 
plan was composed for every 2 fractions. The position of the 
applicator in relation to the tumor and critical organs during 
the day doesn’t change provided that the methodology is 
being correctly observed. Dose plans were optimized for 
maximal tumor dose (D90) and coverage (V100 and V80). The 
dose parameters in the target volume are the following: D 90 
= 7.3 (5.9-9.1) Gy, V 100 = 91.5 (79.2-99.1) %, V 80 = 97.8 
(90.5 -100). Of the patients it was T2bN0M0 – 7 patients, 
T3bN0M0 – 5, T2b-3bN1M0 – 18, T2b-3bN1M1 – 8. 
 
Results: in the results the values of dose rates (D 2 cc / D 0,1 
cc) to organs of risk (bladder, rectum and sigmoid) are the 
following: 3.7 (1.7-7) / 4.8 (2.2 -9.4) Gy; 3.1 (1.2-6) / 4.2 
(1.4 - 8.3) and 3.9 (2.2-5.7) / 5.5 (3.5 -7.6) Gy. During 
follow-up time for 12 months no any acute or late toxicity of 
grade 2 were observed and not observed any difference in 
comparison with the fractionation scheme used previously. 
No one local recurrence were observed, regional recurrence 
in 2 (2 and 7 months), distant metastasis in 1 (12 months). 
The patients have undergone the treatment satisfactorily. 
The number of surgical implantations decreases from 4 to 2. 
According to preliminary data, local radiation reactions are 
not multiple. 
 
Conclusion: The main advantage of this method is the dose 
delivery in a shorter period of time, which allows for a 
greater control of the tumor. This method allows to reduce 
the time of course of brachytherapy to 9 days. Evaluating the 
effectiveness of treatment shows good tolerance of this 
treatment with satisfactory results. This clinical study is 
currently ongoing. 
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Purpose or Objective: To evaluate dosimetric and clinical 
findings of MRI-guided HDR brachytherapy (HDR-BQ) for 
cervical carcinoma. 
 
Material and Methods: From 2008 to 2014: 50 patients. All 
patients had a CT, MRI and pelvic-paraaortic 
lymphadenectomy. Treatment: pelvic(+/-)para-aortic3D/IMRT 
radiotherapy(45Gy) and weekly cisplatin followed by HDR-BQ 
and pelvic node/ parametrial boost 60Gy. Two implants at 
week 6th and 7 th were done: 5 fractions of 6Gy and from 
2011 4 fractions of 7Gy. MRI/TAC was done in each implant. 
There where defined: GTV, CTH-HR, CTV-IR; OAR: rectum, 
bladder and sigmoid. 
 
Results: Patients: T1b2-T2a: 3p, T2b 36p, T3a: 2p; T3B 9p; 
N0: 31p, N1 19p.With a median follow up of 50.6 months(8.1 
– 89.2 months), 5 patients had local recurrence, 6 lymph 
node recurrence, 6 distant metastasis and 36 without 
recurrence. Local control at 5 years was 88%; Ib2-IIB: 93%, III: 
70%. (p:0.07). Lymph node Regional Disease Free 
Survival(RDFS) 5y was 88%; IB2-IIB: 89%, III: 83% (p:ns); for 
pN0: 94%; pN+ iliac-paraaortic: 77% (p: 0.08). Metastasis Free 
Survival 5y was 78%; IIBN0: 78%, IIBN1: 89%, III: 63%. Overall 
